West Paces Advisors Inc. Amgen Inc Transaction History

West Paces Advisors Inc.

$408 Billion
Q3 2024

A detailed history of West Paces Advisors Inc. transactions in Amgen Inc stock. As of the latest transaction made, West Paces Advisors Inc. holds 1,686 shares of AMGN stock, worth $471,995. This represents 0.13% of its overall portfolio holdings.

Number of Shares

1,686

Previous 1,849 8.82%

Holding current value

$471,995

Previous $578 Million 5.97%

% of portfolio

0.13%

Previous 0.15%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$309.38 - $337.38 $50,428 - $54,992	-163 Reduced 8.82%	1,686 $543 Million
Q2 2024 Jul 16, 2024	SELL	$262.75 - $319.31 $2,364 - $2,873	-9 Reduced 0.48%	1,849 $578 Million
Q1 2024 Apr 15, 2024	BUY	$268.87 - $324.56 $10,485 - $12,657	39 Added 2.14%	1,858 $528 Million
Q4 2023 Jan 30, 2024	BUY	$255.7 - $288.46 $136,543 - $154,037	534 Added 41.56%	1,819 $524 Million
Q3 2023 Dec 18, 2023	SELL	$218.65 - $271.46 $49,633 - $61,621	-227 Reduced 15.01%	1,285 $345 Million
Q2 2023 Dec 18, 2023	SELL	$214.27 - $253.37 $33,211 - $39,272	-155 Reduced 9.3%	1,512 $336 Million
Q1 2023 Dec 18, 2023	SELL	$225.79 - $275.2 $9,483 - $11,558	-42 Reduced 2.46%	1,667 $403 Million
Q4 2022 Dec 18, 2023	BUY	$229.03 - $291.01 $391,412 - $497,336	1,709 New	1,709 $449 Million
Q3 2022 Dec 18, 2023	SELL	$224.46 - $253.15 $13,692 - $15,442	-61 Reduced 3.51%	1,675 $378 Million
Q2 2022 Dec 18, 2023	SELL	$230.71 - $256.74 $21,225 - $23,620	-92 Reduced 5.03%	1,736 $422 Million
Q1 2022 Dec 18, 2023	BUY	$219.27 - $242.57 $119,063 - $131,715	543 Added 42.26%	1,828 $442 Million
Q4 2021 Dec 19, 2023	SELL	$198.88 - $227.6 $273,261 - $312,722	-1,374 Reduced 43.28%	1,801 $405 Million
Q3 2021 Dec 19, 2023	BUY	$212.27 - $248.7 $61,346 - $71,874	289 Added 10.01%	3,175 $675 Million
Q2 2021 Dec 19, 2023	SELL	$233.58 - $259.14 $10,511 - $11,661	-45 Reduced 1.54%	2,886 $703 Million
Q1 2021 Dec 19, 2023	BUY	$221.91 - $258.6 $12,648 - $14,740	57 Added 1.98%	2,931 $729 Million
Q4 2020 Dec 19, 2023	SELL	$216.38 - $257.67 $68,808 - $81,939	-318 Reduced 9.96%	2,874 $661 Million
Q3 2020 Dec 19, 2023	SELL	$234.65 - $260.95 $6,335 - $7,045	-27 Reduced 0.84%	3,192 $811 Million
Q2 2020 Dec 19, 2023	BUY	$197.81 - $242.74 $382,564 - $469,459	1,934 Added 150.51%	3,219 $759 Million
Q1 2020 Dec 20, 2023	SELL	$182.24 - $241.7 $702,170 - $931,270	-3,853 Reduced 54.48%	3,219 $653 Million
Q4 2019 Dec 21, 2023	BUY	$189.21 - $243.2 $12,866 - $16,537	68 Added 2.01%	3,447 $831 Million
Q3 2019 Dec 21, 2023	SELL	$174.11 - $208.62 $246,887 - $295,823	-1,418 Reduced 29.56%	3,379 $654 Million
Q2 2019 Dec 21, 2023	SELL	$166.7 - $195.41 $207,208 - $242,894	-1,243 Reduced 20.58%	4,797 $884 Million
Q1 2019 Dec 21, 2023	SELL	$180.87 - $203.88 $183,221 - $206,530	-1,013 Reduced 14.36%	6,040 $1.15 Billion
Q4 2018 Dec 21, 2023	SELL	$178.4 - $208.25 $10,168 - $11,870	-57 Reduced 0.8%	7,053 $1.37 Billion
Q3 2018 Dec 20, 2023	BUY	$185.29 - $208.89 $1.07 Million - $1.21 Million	5,787 Added 450.35%	7,072 $1.47 Billion
Q2 2018 Dec 21, 2023	BUY	$166.05 - $186.51 $2,656 - $2,984	16 Added 0.23%	7,110 $1.31 Billion
Q1 2018 Dec 21, 2023	BUY	$169.43 - $198.0 $319,714 - $373,626	1,887 Added 36.24%	7,094 $1.21 Billion
Q4 2017 Dec 21, 2023	SELL	$168.79 - $188.59 $8,270 - $9,240	-49 Reduced 0.93%	5,207 $905 Million
Q3 2017 Dec 21, 2023	BUY	$167.29 - $191.0 $102,381 - $116,892	612 Added 13.18%	5,256 $980 Million
Q2 2017 Dec 21, 2023	SELL	N/A	-222 Reduced 4.56%	4,644 $800 Million
Q1 2017 Dec 21, 2023	BUY	N/A	426 Added 9.59%	4,866 $798 Million
Q4 2016 Dec 21, 2023	BUY	N/A	3,155	4,440 $649 Million

Others Institutions Holding AMGN

# of Institutions

3,120

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of West Paces Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on West Paces Advisors Inc. with notifications on news.

Account

West Paces Advisors Inc. Amgen Inc Transaction History